Clinical Trial Update: A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial from Eli Lilly evaluating a combination of two approved drugs to enhance treatment of schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Eli Lilly and Company | Conditions: Schizophrenia | Phase 1, Phase 2 | Status: COMPLETED